{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:21:19Z","timestamp":1793996479900,"version":"4.8.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","award":["G-2203-05900"],"award-info":[{"award-number":["G-2203-05900"]}],"id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>The growing use of glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes mellitus (DM2) and obesity necessitates studies about their use in patients with inflammatory bowel diseases (IBD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on patients with DM2 were retrieved from an Israeli nationwide cohort of patients with IBD (epi-IIRN), recording GLP-1 analog exposure for at least 6 months. The primary outcome was poor disease outcomes (ie, composite of steroid dependence, initiation of advanced IBD therapy, hospitalization, surgery, or death). Cox proportional hazard models with time-varying covariables were used to assess the impact of GLP-1 use on outcomes during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 3737 patients (24\u2005338 patient-years) with IBD and DM2 [50.4% ulcerative colitis (UC)], of whom 633 were treated with GLP-1 analogs. Accounting for demographics IBD\/DM2 related variables, medication use, and laboratory measurements, GLP-1 analog use was associated with reduced composite outcome in the full cohort (adjusted hazard ratio [aHR] 0.74, 95% confidence interval [CI] 0.62-0.89) and in each subtype [UC (aHR 0.71, 95% CI 0.52-0.96) and Crohn\u2019s disease (aHR 0.78, 95% CI 0.62-0.99)]. Similar trends were seen in multivariate analyses of each individual outcome, although only hospitalization was significant (aHR 0.74, 95% CI 0.61-0.91). The protective effect of GLP-1 analogs was seen in patients with obesity (aHR 0.61, 95% CI 0.50-0.77), but not in non-obese (aHR 0.94, 95% CI 0.67-1.31).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 analogs are associated with improved outcomes in IBD, specifically in patients with obesity. The mechanisms of these effects require further investigation as well as their role in patients without DM2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjae160","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T12:13:19Z","timestamp":1728994399000},"source":"Crossref","is-referenced-by-count":44,"title":["GLP-1 Analog Use is Associated With Improved Disease Course in Inflammatory Bowel Disease: A Report from the Epi-IIRN"],"prefix":"10.1093","volume":"19","author":[{"given":"Yuri","family":"Gorelik","sequence":"first","affiliation":[{"name":"Rambam Health Care Campus Department of Internal Medicine D, , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itai","family":"Ghersin","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Department of Internal Medicine H, , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Lujan","sequence":"additional","affiliation":[{"name":"The Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, The Hebrew University of Jerusalem , Jerusalem ,","place":["Israel"]},{"name":"The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center , Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Shlon","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Department of Internal Medicine D, , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-5902","authenticated-orcid":false,"given":"Yiska","family":"Loewenberg Weisband","sequence":"additional","affiliation":[{"name":"Innovation Division, Clalit Research Institute , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ben-Tov","sequence":"additional","affiliation":[{"name":"Medical Informatics, Maccabi Health Services , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Matz","sequence":"additional","affiliation":[{"name":"Leumit Health Services , Tel-Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Zacay","sequence":"additional","affiliation":[{"name":"Research Institute, Meuhedet Health Services , Tel Aviv ,","place":["Israel"]},{"name":"Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[{"name":"Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Division of Gastroenterology, Rabin Medical Center , Petah Tikva ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Turner","sequence":"additional","affiliation":[{"name":"The Juliet Keidan Institute of Pediatric Gastroenterology Hepatology and Nutrition, The Hebrew University of Jerusalem , Jerusalem ,","place":["Israel"]},{"name":"The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center , Jerusalem ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-4930","authenticated-orcid":false,"given":"Haggai","family":"Bar-Yoseph","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Department of Gastroenterology, , Haifa ,","place":["Israel"]},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2025041609220070900_CIT0001","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1016\/j.crohns.2012.09.009","article-title":"High prevalence of overweight and obesity in adults with Crohn\u2019s disease: associations with disease and lifestyle factors","volume":"7","author":"Nic Suibhne","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2025041609220070900_CIT0002","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/ecco-jcc\/jjab097","article-title":"Prevalence and impact of obesity on disease-specific outcomes in a population-based cohort of patients with ulcerative colitis","volume":"15","author":"Johnson","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025041609220070900_CIT0003","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.cgh.2019.07.052","article-title":"Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study","volume":"18","author":"Jess","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025041609220070900_CIT0004","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/biomedicines9040383","article-title":"GLP-1 and intestinal diseases","volume":"9","author":"Hunt","year":"2021","journal-title":"Biomedicines"},{"key":"2025041609220070900_CIT0005","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"2025041609220070900_CIT0006","doi-asserted-by":"crossref","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025041609220070900_CIT0007","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025041609220070900_CIT0008","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2147\/CLEP.S151339","article-title":"Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study","volume":"10","author":"Friedman","year":"2018","journal-title":"Clin Epidemiol"},{"key":"2025041609220070900_CIT0009","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","article-title":"Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes","volume":"14","author":"Singh","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025041609220070900_CIT0010","doi-asserted-by":"crossref","first-page":"otad007","DOI":"10.1093\/crocol\/otad007","article-title":"High burden of obesity and low rates of weight loss pharmacotherapy in inflammatory bowel disease: 10-year trend","volume":"5","author":"Elangovan","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2025041609220070900_CIT0011","doi-asserted-by":"crossref","first-page":"630","DOI":"10.14309\/ajg.0000000000000197","article-title":"Impact of obesity on disease activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in inflammatory bowel diseases","volume":"114","author":"Jain","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2025041609220070900_CIT0012","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/2050640620954556","article-title":"Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: results from the Swiss inflammatory bowel disease cohort","volume":"8","author":"Greuter","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2025041609220070900_CIT0013","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.cgh.2005.12.015","article-title":"The impact of increased body mass index on the clinical course of Crohn\u2019s disease","volume":"4","author":"Hass","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025041609220070900_CIT0014","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/DCR.0b013e3182342ccb","article-title":"The impact of obesity on outcomes following major surgery for Crohn\u2019s disease: an American College of Surgeons National Surgical Quality Improvement Program assessment","volume":"54","author":"Causey","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"2025041609220070900_CIT0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/codi.13128","article-title":"Association between high visceral fat area and postoperative complications in patients with Crohn\u2019s disease following primary surgery","volume":"18","author":"Ding","year":"2016","journal-title":"Colorectal Dis"},{"key":"2025041609220070900_CIT0016","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00384-022-04190-y","article-title":"Systematic review and meta-analysis: association between obesity\/overweight and surgical complications in IBD","volume":"37","author":"Jiang","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"2025041609220070900_CIT0017","year":"2024"},{"key":"2025041609220070900_CIT0018","doi-asserted-by":"publisher","first-page":"478","DOI":"10.17235\/reed.2024.10305\/2024","article-title":"Effectiveness and safety of GLP-1 agonist in obese patients with inflammatory bowel disease","volume":"116","author":"Ramos Belinch\u00f3n","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"2025041609220070900_CIT0019","doi-asserted-by":"publisher","first-page":"izae090","DOI":"10.1093\/ibd\/izae090","article-title":"Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity","author":"Desai","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025041609220070900_CIT0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjcard.2010.02.017","article-title":"Relation of C-reactive protein to abdominal adiposity","volume":"106","author":"Brooks","year":"2010","journal-title":"Am J Cardiol"},{"key":"2025041609220070900_CIT0021","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/obr.12003","article-title":"Obesity and C-reactive protein in various populations: a systematic review and meta-analysis","volume":"14","author":"Choi","year":"2013","journal-title":"Obes Rev"},{"key":"2025041609220070900_CIT0022","doi-asserted-by":"crossref","first-page":"851","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu","year":"2017","journal-title":"Arch Med Sci"},{"key":"2025041609220070900_CIT0023","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1053\/j.gastro.2023.06.036","article-title":"Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: results of the constellation study","volume":"165","author":"Yarur","year":"2023","journal-title":"Gastroenterology"},{"key":"2025041609220070900_CIT0024","doi-asserted-by":"crossref","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"2025041609220070900_CIT0025","doi-asserted-by":"crossref","first-page":"8044","DOI":"10.18632\/aging.204953","article-title":"The alleviating effect and mechanism of GLP-1 on ulcerative colitis","volume":"15","author":"Wang","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"2025041609220070900_CIT0026","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1097\/MIB.0000000000000847","article-title":"GLP-1 induces barrier protective expression in Brunner\u2019s glands and regulates colonic inflammation","volume":"22","author":"Bang-Berthelsen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2025041609220070900_CIT0027","first-page":"281","article-title":"A novel use of liraglutide: induction of partial remission in ulcerative colitis and ankylosing spondylitis","volume":"6","author":"Lourie","year":"2019","journal-title":"Clin Med Rev Case Rep"},{"key":"2025041609220070900_CIT0028","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.cgh.2023.01.012","article-title":"Food processing and risk of inflammatory bowel disease: a systematic review and meta-analysis","volume":"21","author":"Narula","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025041609220070900_CIT0029","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025041609220070900_CIT0030","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2025041609220070900_CIT0031","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00228-016-2149-3","article-title":"Use of pharmacy dispensing data to measure adherence and identify nonadherence with oral hypoglycemic agents","volume":"73","author":"Sodihardjo-Yuen","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025041609220070900_CIT0032","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/1475-6773.13714","article-title":"Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data","volume":"57","author":"Fontanet","year":"2022","journal-title":"Health Serv Res"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjae160\/60778551\/jjae160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjae160\/60778551\/jjae160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjae160\/60778551\/jjae160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T09:22:24Z","timestamp":1744795344000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjae160\/7833454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae160","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,10,23]]},"article-number":"jjae160"}}